Status:
UNKNOWN
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Lead Sponsor:
Akeso
Conditions:
Resectable Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
Detailed Description
Phase II clinical study of AK112, an anti-PD-1 and VEGF bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer
Eligibility Criteria
Inclusion
- 1、18 to 75 years old
- 2、Be able and willing to provide written informed consent and to comply with all requirements of study participation
- 3、Histologically confirmed resectable stage II-IIIB NSCLC
- 4、Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- 5、Has adequate organ function
- 6、All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.
Exclusion
- Is currently participating in a study of an investigational agent or using an investigational device
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has an active infection requiring systemic therapy
- Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected)
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
- Has received a live virus vaccine within 30 days prior to first dose of study treatment
- Is pregnant, breastfeeding, or expecting to conceive or father a child within the projected duration of the study including 120 days following the last dose of study treatment.
Key Trial Info
Start Date :
February 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 20 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05247684
Start Date
February 20 2022
End Date
January 20 2025
Last Update
February 21 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.